» Articles » PMID: 32751561

Dengue: A Minireview

Overview
Journal Viruses
Publisher MDPI
Specialty Microbiology
Date 2020 Aug 6
PMID 32751561
Citations 104
Authors
Affiliations
Soon will be listed here.
Abstract

Dengue, caused by infection of any of four dengue virus serotypes (DENV-1 to DENV-4), is a mosquito-borne disease of major public health concern associated with significant morbidity, mortality, and economic cost, particularly in developing countries. Dengue incidence has increased 30-fold in the last 50 years and over 50% of the world's population, in more than 100 countries, live in areas at risk of DENV infection. We reviews DENV biology, epidemiology, transmission dynamics including circulating serotypes and genotypes, the immune response, the pathogenesis of the disease as well as updated diagnostic methods, treatments, vector control and vaccine developments.

Citing Articles

Development of a multi-epitope vaccine candidate to combat SARS-CoV-2 and dengue virus co-infection through an immunoinformatic approach.

Mandal S, Chanu W, Natarajaseenivasan K Front Immunol. 2025; 16:1442101.

PMID: 40079004 PMC: 11897530. DOI: 10.3389/fimmu.2025.1442101.


Maternal and foetal outcomes in women with gestational Dengue: A systematic review.

Velez Jaramillo Y, Reveiz Montes M, Galvan-Barrios J, Picon-Jaimes Y Infez Med. 2025; 33(1):15-28.

PMID: 40071256 PMC: 11892438. DOI: 10.53854/liim-3301-3.


Whole genome sequencing and phylogenetic analysis of dengue virus in Central Nepal from 2022 to 2023.

Chi M, Katuwal N, Shrestha A, Madhup S, Tamrakar D, Shrestha R BMC Glob Public Health. 2025; 3(1):18.

PMID: 40045383 PMC: 11884168. DOI: 10.1186/s44263-025-00135-z.


Knowledge, Attitudes, and Practices for the Prevention and Vector Control of Dengue in a Colombian Rural Population: A Mixed Method Study.

Rossana L, Katty E, Mayra B SAGE Open Nurs. 2025; 11:23779608241302713.

PMID: 40013006 PMC: 11863257. DOI: 10.1177/23779608241302713.


Current Dengue Virus Vaccine Developments and Future Directions.

Anumanthan G, Sahay B, Mergia A Viruses. 2025; 17(2).

PMID: 40006967 PMC: 11861685. DOI: 10.3390/v17020212.


References
1.
Perez A, Garcia G, Sierra B, Alvarez M, Vazquez S, Cabrera M . IL-10 levels in Dengue patients: some findings from the exceptional epidemiological conditions in Cuba. J Med Virol. 2004; 73(2):230-4. DOI: 10.1002/jmv.20080. View

2.
Twiddy S, Holmes E, Rambaut A . Inferring the rate and time-scale of dengue virus evolution. Mol Biol Evol. 2003; 20(1):122-9. DOI: 10.1093/molbev/msg010. View

3.
Yakob L, Funk S, Camacho A, Brady O, Edmunds W . Aedes aegypti Control Through Modernized, Integrated Vector Management. PLoS Curr. 2017; 9. PMC: 5319873. DOI: 10.1371/currents.outbreaks.45deb8e03a438c4d088afb4fafae8747. View

4.
Capeding M, Tran N, Hadinegoro S, Ismail H, Chotpitayasunondh T, Chua M . Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. Lancet. 2014; 384(9951):1358-65. DOI: 10.1016/S0140-6736(14)61060-6. View

5.
Ritchie S . Wolbachia and the near cessation of dengue outbreaks in Northern Australia despite continued dengue importations via travellers. J Travel Med. 2018; 25(1). DOI: 10.1093/jtm/tay084. View